Phase II study of cisplatin, docetaxel, and irinotecan, followed by gefitinib, gemcitabine and vinorelbine for patients with non-small-cell lung cancer harboring active EGFR gene mutations (OLCSG0704)
Phase 2
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000002095
- Lead Sponsor
- Okayama Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Symptomatic brain metastasis, Symptomatic malignant pleural/pericardial effusion Active concomitant malignancy Unstable angina, recent myocardial infarction, heart failure Uncontrolled diabetes or hypertension Pregnant or lactating women Other severe complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Response rate, progression-free survival, adverse events, treatment compliance, relationship between response rate and expression levels of ERCC1 and thioredoxin in the tumors, Comparison of outcomes with EGFR mutation negative patients